Trademark: 79134010
Word
GMP ORPHAN DRUGS FOR ORPHAN DISEASES
Status Date
Saturday, February 6, 2021
Registration Number
4541221
Registration Date
Tuesday, June 3, 2014
Filing Date
Tuesday, May 14, 2013
Published for Opposition
Tuesday, March 18, 2014
5 Pharmaceutical and veterinary products for the treatment of orphan diseases; medication for the treatment of orphan diseases; pharmaceutical and veterinary products for pediatric use for the treatment of orphan diseases; medication for pediatric use for the treatment of orphan diseases; chemical preparations for medical or pharmaceutical use in the treatment of childhood diseases; pharmaceutical and veterinary products and medicines for the treatment of orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy; pharmaceutical and veterinary products and medicines for the treatment of hyperammonemia of all kinds
44 Medical services; medical and sanitary care, namely, telemedecine services including remote diagnosis or medical follow-up; medical testing for the diagnosis and treatment of persons; providing medical advice on health matters in the field of medication administration; providing medical advisory services relating to medical apparatus and instruments; medical diagnosis services of orphan diseases; providing medical information, all the aforesaid services in connection with the treatment of childhood and orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy
10 [ Medical, surgical and veterinary apparatus and instruments, for diagnosis and treatment, particularly in connection with orphan diseases; medical devices containing chemical products for diagnostic use of orphan diseases; medical diagnosis apparatus and instruments to diagnose orphan diseases; automatic testing apparatus to diagnose orphan diseases, for medical use, also in the form of kits; medical apparatus and instruments in the form of kits for detecting the presence of analytes in biological fluids, other fluids and other structures; immunochemical testing apparatus for medical use; blood testing apparatus; radiological apparatus for medical use; resuscitation apparatus; medical imaging apparatus incorporating medical imaging software; needles for medical use; gloves for medical use; syringes for medical use; inhalers for medical purposes; injectors for medical use; X-ray photographs for medical use; radiology screens for medical use; receptacles for applying medicines; containers especially made for medical waste; probes for medical use; stethoscopes; heart pacemakers; thermometers for medical use; cases fitted for medical instruments for use by surgeons or doctors ]
42 Evaluations, assessments and research in the fields of science; research and development services in the field of medicine; research and development of new products for others, namely, medical diagnosis apparatus; research and development in the field of biotechnology; scientific research for medical purposes; scientific laboratory services in the medical field; all the aforesaid services in connection with the treatment of childhood and orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy
The mark consists of the literal stylized wording "gmp orphan drugs for orphan diseases". The wording "gmp" and "drugs for orphan diseases" appear in the color white, and the wording "orphan" is in black. The wording "gmp" is displayed with the letter "o" of the wording "orphan" above the wording "drugs for orphan diseases" all in a blue box, and the letters "rphan" appear outside of the box.
The color(s) white, blue and black is/are claimed as a feature of the mark.
"ORPHAN" AND "DRUGS FOR ORPHAN DISEASES"
Jun 9, 2023
International Registration Renewed
Jun 3, 2023
Courtesy Reminder - Sec. 71 (10-Yr) E-Mailed
Dec 5, 2021
Partial Invalidation Processed By The Ib
Oct 27, 2021
Partial Invalidation Of Reg Ext Protection Sent To Ib
Oct 27, 2021
Invalidation Processed
Oct 6, 2021
Partial Invalidation Of Reg Ext Protection Created
Feb 6, 2021
Notice Of Acceptance Of Sec. 71 - E-Mailed
Feb 6, 2021
Registered - Partial Sec 71 Accepted
Feb 1, 2021
Case Assigned To Post Registration Paralegal
Jan 29, 2021
Change Of Name/Address Rec'd From Ib
Dec 3, 2020
Teas Section 71 Received
Jun 3, 2019
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Feb 7, 2019
New Representative At Ib Received
Feb 8, 2018
Change Of Name/Address Rec'd From Ib
Mar 3, 2016
New Representative At Ib Received
Nov 21, 2014
Final Decision Transaction Processed By Ib
Oct 21, 2014
Final Disposition Notice Sent To Ib
Oct 21, 2014
Final Disposition Processed
Sep 3, 2014
Final Disposition Notice Created, To Be Sent To Ib
Jun 3, 2014
Registered-Principal Register
Mar 18, 2014
Official Gazette Publication Confirmation E-Mailed
Mar 18, 2014
Published For Opposition
Mar 14, 2014
Notification Processed By Ib
Feb 26, 2014
Notification Of Possible Opposition Sent To Ib
Feb 26, 2014
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Feb 26, 2014
Notification Of Notice Of Publication E-Mailed
Feb 7, 2014
Law Office Publication Review Completed
Feb 5, 2014
Approved For Pub - Principal Register
Feb 5, 2014
Teas/Email Correspondence Entered
Feb 5, 2014
Correspondence Received In Law Office
Jan 30, 2014
Assigned To Lie
Jan 22, 2014
Teas Response To Office Action Received
Sep 30, 2013
Refusal Processed By Ib
Sep 11, 2013
Non-Final Action Mailed - Refusal Sent To Ib
Sep 11, 2013
Refusal Processed By Mpu
Sep 11, 2013
Non-Final Action (Ib Refusal) Prepared For Review
Sep 10, 2013
Non-Final Action Written
Sep 3, 2013
Assigned To Examiner
Aug 16, 2013
Application Filing Receipt Mailed
Aug 12, 2013
New Application Office Supplied Data Entered
Aug 8, 2013
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
